Anthrax treatment study for patients who received raxibacumab
Part of Infections clinical trials.
This study observes people in the US who have been diagnosed with systemic anthrax and treated with a medication called raxibacumab, which was given from a national emergency supply. The goal is to learn more about how this treatment works in real-world cases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of systemic anthrax (anthrax that has spread beyond the skin or affects the whole body).
- You must have been treated with raxibacumab from the Strategic National Stockpile (a US emergency supply).
- You must be willing to follow the study procedures and give written consent (or have a legal representative do so if you are a minor or unable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people who have symptoms of inhalational anthrax after a mass exposure. It tests a medicine called raxibacumab to see if it helps and is safe. Anyone who receives this medicine as part of their care can join.
This study looks at patients who have been diagnosed with or are suspected to have systemic anthrax and are being treated with the medicine AIGIV. It aims to understand how well the treatment works and whether it is safe. The results may help improve care for people with this serious infection.
This study tests a treatment called AIGIV (sometimes sold as Anthrasil) for people who get anthrax by breathing in the germs. The treatment is made from human antibodies that fight the anthrax toxin, and the study checks if it is safe and helps patients recover.
This study looks for people who have recently completed standard treatment for drug-sensitive TB. Researchers want to check if certain tests can predict long-term health outcomes after treatment.
This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.
This trial tests a new medication called Xeligekimab for people with a type of arthritis called non-radiographic axial spondyloarthritis, which causes inflammation in the spine and joints. The goal is to see if the drug can reduce symptoms like pain and stiffness.
Hear when a new Infections, Bacterial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.